Inositol Cancer Research Results

Ins, Inositol: Click to Expand ⟱
Features:
Inositol is a form of sugar your body needs to grow. myo-inositol is a sugar alcohol and a glucose isomer found in many food including grains and fruits.

Inositol — Inositol is a naturally occurring six-carbon cyclitol (sugar alcohol-like carbohydrate), with myo-inositol being the predominant biologically active stereoisomer in humans and the form most commonly used as an oral supplement. It is formally classified as a nutrient/metabolic signaling molecule rather than an established anticancer drug; common abbreviations include MI, myo-Ins, and Ins. Myo-inositol is obtained from foods and is also synthesized endogenously from glucose-6-phosphate through ISYNA1-dependent metabolism. It is a precursor for phosphatidylinositol and phosphoinositide second-messenger systems. Myo-inositol should be distinguished from inositol hexaphosphate (IP6/phytic acid), which has substantially more preclinical anticancer literature and is listed separately in this database.

Primary mechanisms (ranked):

  1. Suppression or normalization of PI3K/Akt-associated oncogenic signaling in responsive tumor and premalignant-cell contexts.
  2. Suppression of IL-6/STAT3-associated inflammatory tumor signaling and modulation of the tumor immune microenvironment, including macrophage phenotype.
  3. Activation of the miR-125a-5p/IP6K1 tumor-suppressive axis, reducing migration, epithelial-mesenchymal transition and metastatic potential in responsive breast-cancer models.
  4. Antiproliferative and pro-differentiation effects with remodeling of cell-cycle, cytoskeletal and apoptosis-associated proteins.
  5. Metabolic modulation involving insulin signaling, glucose metabolism, AMPK and phosphoinositide signaling; effects are strongly tumor- and metabolic-context dependent.

Bioavailability / PK relevance: Myo-inositol is orally absorbed through sodium-dependent inositol transport systems, with human serum concentrations peaking approximately 1.5–3 hours after oral administration. A 100 mg/kg oral dose produced an estimated peak serum concentration of about 100 µM in a small human kinetic study. Bioavailability varies with formulation and can be reduced by competing D-chiro-inositol and some sugars/transporter substrates. Renal elimination is important. High-dose oncology studies have used approximately 18 g/day; gastrointestinal intolerance becomes dose-limiting at higher doses.

In-vitro vs systemic exposure relevance: Exposure is concentration-driven. A recent DU-145 prostate-cancer study reported an approximate myo-inositol IC50 of 0.06 mg/mL after 72 hours, equivalent to about 330 µM; this is several-fold above the approximately 100 µM peak serum concentration observed after a 100 mg/kg oral human dose, although substantially higher oral doses have been used clinically. Some mechanistic experiments use still higher concentrations, so direct systemic translation of in-vitro cytotoxicity should be interpreted cautiously. Chemopreventive and signaling effects may occur below directly cytotoxic concentrations.

Clinical evidence status: RCT-level chemoprevention evidence but no demonstrated anticancer efficacy. A randomized double-blind phase IIb trial used myo-inositol 9 g twice daily for six months in smokers with bronchial dysplasia. It did not significantly improve the primary dysplasia-response endpoint versus placebo, although BAL IL-6 decreased and responders showed reduced airway PI3K-activation signatures. Earlier phase I work established approximately 18 g/day as a tolerated dose and suggested lesion-regression activity. Myo-inositol is therefore best classified as an experimental chemopreventive/metabolic adjunct rather than an established cancer treatment.

Inositol Cancer-Relevant Mechanisms

Rank Pathway / Axis Cancer Cells Normal Cells Primary Effect Notes / Interpretation
1 PI3K / Akt signaling ↓ (context-dependent) ↔ / physiological regulation Reduced proliferative and survival signaling One of the most reproducible proposed myo-inositol anticancer mechanisms. Reduced airway PI3K-activation signatures were observed particularly among clinical responders, but PI3K suppression is not universal across models.
2 IL-6 / STAT3 inflammatory signaling ↓ ↓ pathological inflammatory signaling Reduced tumor-promoting inflammation Myo-inositol reduced IL-6-associated pathways and phospho-STAT3 in a KRAS-driven lung-cancer model. Human bronchial-dysplasia trial also demonstrated ↓ BAL IL-6.
3 miR-125a-5p / IP6K1 axis miR-125a-5p ↑
IP6K1 ↓		 Not established Reduced migration, EMT and metastasis Demonstrated in MDA-MB-231 triple-negative breast-cancer cells. Hormone-responsive MCF-7 cells were comparatively resistant, demonstrating substantial subtype dependence.
4 EMT and metastatic phenotype ↓ (model-dependent) ↔ Reduced invasion and metastatic potential Closely linked to PI3K/Akt and miR-125a-5p/IP6K1 modulation rather than a completely independent mechanism.
5 Cell proliferation ↓ (dose-dependent) ↔ / slight effect Growth inhibition Recent DU-145 experiments reported approximately 50% viability inhibition near 0.06 mg/mL after 72 hours while mouse L929 fibroblasts retained approximately 90% viability at the tested concentration.
6 Apoptosis-associated signaling ↑ (model-dependent) ↔ Promotion of tumor-cell death Proteomic changes in DU-145 cells included ↑ APAF1 and alterations in other apoptosis/stress-associated proteins. Evidence for direct myo-inositol-induced apoptosis is substantially less extensive than for IP6.
7 Macrophage and tumor microenvironment signaling Indirect suppression M1 antitumor phenotype ↑ Less tumor-supportive microenvironment KRAS-driven mouse lung lesions showed reduced macrophage recruitment and phenotype remodeling toward an antitumor M1 profile.
8 ERK / MAPK signaling ↓ (context-dependent) ↔ / physiological regulation Reduced mitogenic signaling Supported mainly by broader inositol literature. Evidence specifically isolating unphosphorylated myo-inositol from IP6 and other inositol phosphates is less robust.
9 Glucose metabolism / insulin signaling Modulated (context-dependent) Insulin sensitivity ↑ Metabolic normalization Myo-inositol has well-established metabolic signaling activity, but the consequences for cancer are complex and cannot be assumed to be uniformly antitumor.
10 AMPK metabolic signaling ↓ / mixed (context-dependent) Context-dependent Altered metabolic-state signaling A mechanistic caution: inositol can inhibit AMPK in some settings. Because AMPK can either suppress proliferation or promote survival under metabolic stress, this pathway may produce opposing effects depending on tumor state.
11 SLC5A3-dependent inositol uptake Potentially ↑ growth Physiological uptake Context-dependent tumor nutrient support Important paradoxical mechanism. Some NSCLC cells overexpress SLC5A3 and depend on intracellular myo-inositol for Akt-mTOR activity and proliferation, indicating that greater inositol availability is not intrinsically anticancer in every tumor.
12 Clinical Translation Constraint Context-dependent response Generally well tolerated Limits therapeutic interpretation Phase IIb bronchial-dysplasia RCT failed to demonstrate a significant overall primary-endpoint benefit. Tumor genotype, estrogen signaling, transporter expression and metabolic state appear capable of determining response. High oral doses can cause gastrointestinal adverse effects.


Scientific Papers found: Click to Expand⟱
7616- Ins,    A phase I study of myo-inositol for lung cancer chemoprevention
- Trial, Nor, NA
*Dose↝, *toxicity↝, *BP↓,
7703- Ins,    Inositol hexaphosphate-induced cellular response in myeloid leukemia cells is mediated by nicotinamide adenine dinucleotide phosphate oxidase activation
- in-vitro, AML, PLB-985
TumCG↓, TumCD↑, Diff↑, NOX2↑, ROS↑,
7648- Ins,    Suppression of lung and liver carcinogenesis in mice by oral administration of myo-inositol
- in-vivo, Liver, NA
AntiCan↑, Dose↝, Risk↓, chemoPv↑,
7647- Ins,    Chemoprevention of pulmonary carcinogenesis by myo-inositol
- Review, Lung, NA
AntiTum↑,
7643- Ins,  IP6,    Efficacy of IP6 + inositol in the treatment of breast cancer patients receiving chemotherapy: prospective, randomized, pilot clinical stud
- Trial, BC, NA
RBC↑, QoL↑, Synergy↑, Imm↑, ChemoSen↑, chemoP↑, Dose↝,
7641- Ins,    Overview of Inositol and Inositol Phosphates on Chemoprevention of Colitis-Induced Carcinogenesis
- Review, CRC, NA
AntiCan↑, p‑Akt↓, TF-Ag↓, *PI3K↓, *AP-1↓, *DNArepair↑, *BioAv↑, *BBB↑, *other↑, *PGE2↓,
7639- Ins,    Myo-Inositol Reverses TGF-β1-Induced EMT in MCF-10A Non-Tumorigenic Breast Cells
- in-vitro, Nor, MCF10
EMT↓, E-cadherin↑, AntiCan↑, MMP9↓,
7638- Ins,    d-Chiro-Inositol in Clinical Practice: A Perspective from the Experts Group on Inositol in Basic and Clinical Research (EGOI)
- Review, Nor, NA
*Insulin↝, *CYP19↓, *Dose↝, *Dose↝, *other↝, *Insulin↓, *IRes↓, *Obesity↓, *BioAv↝,
7637- Ins,    Investigating the mechanism of inositol against paclitaxel chemoresistance on triple-negative breast cancer by using 7T multiparametric MRI and mitochondrial changes
- vitro+vivo, BC, 4T1
TumVol↓, Dose↝, *toxicity↓, AMPK↓, Ki-67↓,
7636- Ins,    Myo-Inositol: Pharmacokinetics, Biological Functions, and Therapeutic Potential in Liver Protection: Insights from Preclinical Models
- Review, Nor, NA
*glucose↝, *lipid-P↓, *ROS↓, *BioAv↑, *hepatoP↑, *Inflam↓, *MMP↑, *ATP↑, *GutMicro↑, *Dose↝, *Half-Life↝, *BioAv↑, *Synergy↑, *hepatoP↑, *SOD↑, *Catalase↑, *Casp3↓, *ALAT↓, *AST↓, *AMPK↑, *SREBP1/SREBF1↑, NA↑,
7634- Ins,    Risk of reduced intestinal absorption of myo-inositol caused by D-chiro-inositol or by glucose transporter inhibitors
- Trial, Nor, NA
*BioAv↓,
7633- Ins,    Myo-inositol in a new pharmaceutical form: a step forward to a broader clinical use
- Trial, Nor, NA
*BioAv↑, *toxicity↓,
7632- Ins,    The paradoxical role of inositol in cancer: a consequence of the metabolic state of a tumor
- Review, Var, NA
AMPK↑, AntiCan⇅, p‑Akt↓, PI3K↓,
7631- Ins,  IP6,    Broad Spectrum Anticancer Activity of Myo-Inositol and Inositol Hexakisphosphate
- Review, Var, NA
other↑, p‑pRB↓, TumCCA↑, PI3K↓, Akt↓, ERK↓, NF-kB↓, COX2/PTGS2↓, PGE2↓, PSEN1/PS1↓, EMT↓, Wnt↓, β-catenin/ZEB1↓, NOTCH1↓, N-cadherin↓, Snail↓, E-cadherin↑, fascin↓, Cofilin↓, MMPs↓, ROCK1↓, Dose↝, other↝, selectivity↑, *ROS↓, *lipid-P↓, ROS↑, NK cell↑, Imm↑, TNF-α↓, ChemoSen↑, Dose↑, toxicity↓, QoL↑, chemoP↑, OS↑, Dose↝, Insulin↓, glucose↝, lipoGen↓, Synergy↑,
7635- Ins,    The Role of Inositols in Endocrine and Neuroendocrine Tumors
- Review, Thyroid, NA
*Dose↝, VEGF↓, Imm↑, NK cell↑, Synergy↑, PI3K↓, Akt↓, EMT↓, MAPK↓, Wnt↓, NF-kB↓, IRes↓, *ROS↓, TumVol↓, *TSHR↓,
7630- Ins,    Modulation of both Insulin Resistance and Cancer Growth by Inositol
- Review, Var, NA - Review, Diabetic, NA
*IRes↓, *AntiDiabetic↑, *glucose↝, AntiCan↑, PI3K↓, Akt↓, Glycolysis↓, STK11/LKB1↑, *FASN↓, *LDL↓, *FFA/NEFA↓, *ROS↓, ROS↑, IGF-1↓,
7629- Ins,    Reduced IL-6 levels and tumor-associated phospho-STAT3 are associated with reduced tumor development in a mouse model of lung cancer chemoprevention with myo-inositol
- in-vivo, Lung, NA
AntiCan↑, TumVol↓, PI3K↓, IL6↓, p‑STAT3↓, chemoPv↑,
7615- Ins,    A Randomized Phase IIb Trial of myo-Inositol in Smokers with Bronchial Dysplasia
- Trial, Nor, NA
*Dose↝, *IL6↓, *PI3K↓,
7628- Ins,    Proteomic Analysis of Anticancer Effect of Myo-inositol in Human Prostate Cancer (DU-145) Cell Line
- in-vitro, Pca, DU145
tumCV↓, annexin II↓, Cofilin↓, Rho↑, APAF1↑, TRAF2↑, Apoptosis↑, PI3K↓, Akt↓,
7617- Ins,    miR-125a-5p impairs the metastatic potential in breast cancer via IP6K1 targeting
- in-vitro, BC, NA
PI3K↓, Akt↓, TumMeta↓, miR-125b↝, IP6K1↓,
7721- IP6,  Ins,    Effect of phytic acid and inositol on the proliferation and apoptosis of cells derived from colorectal carcinoma
- in-vitro, CRC, HT-29 - in-vitro, CRC, SW480 - in-vitro, CRC, SW-620
Dose↝, TumCP↓, Casp3↑, Apoptosis↑,
7702- IP6,  Ins,  capec,    Inositol Hexakisphosphate and Inositol Enhance the Inhibition of Colorectal Cancer Growth and Liver Metastasis by Capecitabine in a Mouse Model
- in-vivo, CRC, NA
Dose↝, AntiTum↑, OS↑, TumW↓, TumMeta↓, E-cadherin↑, N-cadherin↓, Vim↓, TNF-α↓, IL6↓, IL8↓, ChemoSen↑,
7697- IP6,  Ins,    Combination of Inositol Hexaphosphate and Inositol Inhibits Liver Metastasis of Colorectal Cancer in Mice Through the Wnt/β-Catenin Pathway
- in-vivo, CRC, NA
TumMeta↓, OS↑, TumW↓, Wnt↓, TCF7/TCF1↓, cMyc↓,
7696- IP6,  Ins,    The Combination of Inositol Hexaphosphate and Inositol Inhibits Metastasis of Colorectal Cancer Cells by Upregulating Claudin 7
- vitro+vivo, Colon, SW48 - in-vitro, Colon, SW-620
AntiCan↑, CLDN7↑, EMT↓, E-cadherin↑, N-cadherin↓, Synergy↑, TumCG↓,
7690- IP6,  Ins,    Inositol Hexaphosphate (IP6) and Colon Cancer: From Concepts and First Experiments to Clinical Application
- Review, Colon, NA
AntiCan↑, Imm↑, antiOx↑, TumCP↓, Diff↑, TumCG↓, Synergy↑, P21↓, p27/CDKN1B↓, pRB↓, TumCCA↑, PI3K↓, Akt↓, PKCδ↓, RAS↓, ERK↓, NF-kB↓, Inflam↓, MMP9↓, IronCh↑, NK cell↑, selectivity↑, ChemoSen↑, chemoP↑, toxicity↓, Remission↑,
7646- IP6,  Ins,    Protection against cancer by dietary IP6 and inositol
- Review, Var, NA
*antiOx↑, TumCG↓, TumMeta↓, Imm↑, kidSt↓, LDL↓, TumCCA↑, TumCP↓, Diff↑, ChemoSen↑, QoL↑,
7645- IP6,  Ins,    Anticancer Properties of Inositol Hexaphosphate and Inositol: An Overview
- in-vitro, Var, NA
AntiCan↑, TumCP↓, Apoptosis↑, Diff↑, p27/CDKN1B↓, pRB↓, PI3K↓, RAS↓, ERK↓, Akt↓, NF-kB↓, Inflam↓, AntiTum↓,
7640- IP6,  Ins,    Effects of Inositol Hexaphosphate and Myo-Inositol Administration in Breast Cancer Patients during Adjuvant Chemotherapy
- Trial, BC, NA
*antiOx↑, QoL↑, RBC↑, HemoG↑, WBC↑, chemoP↑, Dose↝,

Showing Research Papers: 1 to 28 of 28

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 28

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

NA↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   NOX2↑, 1,   ROS↑, 3,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

Insulin↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↓, 1,   AMPK↑, 1,   glucose↝, 1,   Glycolysis↓, 1,   LDL↓, 1,   lipoGen↓, 1,  

Cell Death(tgid=5) ⓘ

APAF1↑, 1,   Apoptosis↑, 3,   Casp3↑, 1,   TumCD↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 7,   p‑Akt↓, 2,   ERK↓, 3,   IP6K1↓, 1,   MAPK↓, 1,   PI3K↓, 9,   PKCδ↓, 1,   RAS↓, 2,   p‑STAT3↓, 1,   STK11/LKB1↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

cMyc↓, 1,   miR-125b↝, 1,   other↑, 1,   other↝, 1,   tumCV↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

Ki-67↓, 1,   P21↓, 1,   p27/CDKN1B↓, 2,   pRB↓, 2,   p‑pRB↓, 1,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Diff↑, 4,   IGF-1↓, 1,   Ki-67↓, 1,   NOTCH1↓, 1,   TumCG↓, 4,   TumCP↓, 4,   Wnt↓, 3,  

Migration(tgid=13) ⓘ

annexin II↓, 1,   Cofilin↓, 2,   E-cadherin↑, 4,   EMT↓, 4,   fascin↓, 1,   MMP9↓, 2,   MMPs↓, 1,   N-cadherin↓, 3,   Rho↑, 1,   ROCK1↓, 1,   Snail↓, 1,   TumMeta↓, 4,   Vim↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

VEGF↓, 1,  

Barriers & Transport(tgid=15) ⓘ

CLDN7↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   IL6↓, 2,   IL8↓, 1,   Imm↑, 5,   Inflam↓, 2,   NF-kB↓, 4,   NK cell↑, 3,   PGE2↓, 1,   TCF7/TCF1↓, 1,   TNF-α↓, 2,   TRAF2↑, 1,  

Protein Aggregation(tgid=19) ⓘ

PSEN1/PS1↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 5,   Dose↑, 1,   Dose↝, 8,   selectivity↑, 2,   Synergy↑, 5,  

Clinical Biomarkers(tgid=22) ⓘ

HemoG↑, 1,   IL6↓, 2,   IRes↓, 1,   RBC↑, 2,   TF-Ag↓, 1,   WBC↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 8,   AntiCan⇅, 1,   AntiTum↓, 1,   AntiTum↑, 2,   chemoP↑, 4,   chemoPv↑, 2,   kidSt↓, 1,   OS↑, 3,   QoL↑, 4,   Remission↑, 1,   Risk↓, 1,   toxicity↓, 2,   TumVol↓, 3,   TumW↓, 2,  
Total Targets: 97

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 2,   Catalase↑, 1,   lipid-P↓, 2,   ROS↓, 4,   SOD↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

Insulin↓, 1,   Insulin↝, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,   AMPK↑, 1,   ATP↑, 1,   FASN↓, 1,   FFA/NEFA↓, 1,   glucose↝, 2,   LDL↓, 1,   SREBP1/SREBF1↑, 1,  

Cell Death(tgid=5) ⓘ

Casp3↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

PI3K↓, 2,  

Transcription & Epigenetics(tgid=7) ⓘ

other↑, 1,   other↝, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNArepair↑, 1,  

Migration(tgid=13) ⓘ

AP-1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,   MMP↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL6↓, 1,   Inflam↓, 1,   PGE2↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

CYP19↓, 1,   TSHR↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 4,   BioAv↝, 1,   Dose↝, 6,   Half-Life↝, 1,   Synergy↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   AST↓, 1,   BP↓, 1,   IL6↓, 1,   IRes↓, 2,  

Functional Outcomes(tgid=23) ⓘ

AntiDiabetic↑, 1,   hepatoP↑, 2,   Obesity↓, 1,   toxicity↓, 2,   toxicity↝, 1,  

Infection & Microbiome(tgid=24) ⓘ

GutMicro↑, 1,  
Total Targets: 45

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:101  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page